ADC Therapeutics SA (ADCT) Year-over-year earnings per share growth for the last twelve months

adctherapeutics.com (ADCT) - corporate logo

The slow clinical adoption of Zynlonta and equity dilution are weighing on the finances of ADC Therapeutics (ADCT). The current level of quarterly EPS growth illustrates this trend, where the 45.70 mark serves as a critical threshold. Outsourced manufacturing ensures supply stability, while the development of targeted therapy relies on highly compensated scientists and generous stock option programs.

adctherapeutics.com (ADCT) - Year-over-year earnings per share growth for the last 12 months from 07/04/2022 to 11/16/2026

Comprehensive metric breakdowns and analytics for ADC Therapeutics (ADCT)

- market value and analyst target forecast:
Basic company analysis:ADC Therapeutics Corp, ADCT
Flagship merchandise of ADC Pharma

Quarterly EPS growth measures the percentage change in net income per share compared to the same period last year. This metric allows for an assessment of capital management efficiency and business scaling rates. The quarterly EPS trend captured on GURU.Markets visualizes the cyclicality of the issuer's returns. For ADC Therapeutics (ADCT), this indicator reflects the financial success of the commercialization of the drug ZYNLONTA. A positive trend confirms the growing market share of targeted oncology therapy.

Who ADC Therapeutics competes with

tgtherapeutics.com (TGTX) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Arcellx Therapeutics (ACLX)|Year-over-year earnings per share growth for the last twelve months Disc Medicine Inc|Earnings per share growth in annualized terms for the last twelve months Syndax Pharmaceuticals SNDX|Quarterly EPS earnings growth KURA|Foghorn Therapeutics Inc. - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months vorbio.com VOR|NKTX: Year-over-year earnings per share growth for the last 12 months|COEP - Year-over-year earnings per share growth for the last twelve months|Actinium Pharmaceuticals, Inc. (ATNM) - Year-over-year net earnings per share growth for the last 12 months|ESLA (Estrella Immunopharma) - Year-over-year net earnings per share growth for the last 12 months|CASI - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Marker Bio|Quarterly EPS earnings growth IN8bio, Inc.|Year-over-year earnings per share growth for the last twelve months Eterna Therapeutics Inc (ERNA)|Year-over-year net earnings per share change for the last twelve months gtbiopharma.com|Quarterly EPS earnings growth APTO (Aptose Biosciences)|Quarterly EPS earnings growth Bio-Path BPTH|MEI Pharma Inc - Quarterly EPS earnings growth|VINC (Vincerx Pharma Inc.) - Year-over-year earnings per share growth for the last 12 months